Last reviewed · How we verify
estrogen therapy
Estrogen therapy replaces or supplements endogenous estrogen by binding to estrogen receptors (ERα and ERβ) throughout the body to restore hormonal balance.
Estrogen therapy replaces or supplements endogenous estrogen by binding to estrogen receptors (ERα and ERβ) throughout the body to restore hormonal balance. Used for Vasomotor symptoms (hot flashes, night sweats) in postmenopausal women, Moderate to severe vulvovaginal atrophy, Osteoporosis prevention in postmenopausal women.
At a glance
| Generic name | estrogen therapy |
|---|---|
| Also known as | white tablet of cycloprogynova, Norelgesetromin, Ethinyl estradiol |
| Sponsor | Beni-Suef University |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
Estrogen acts as a ligand for nuclear estrogen receptors, modulating gene transcription and cellular signaling pathways. This restores physiological estrogen levels in postmenopausal women or those with estrogen deficiency, alleviating vasomotor symptoms, supporting bone density, and maintaining cardiovascular and urogenital health.
Approved indications
- Vasomotor symptoms (hot flashes, night sweats) in postmenopausal women
- Moderate to severe vulvovaginal atrophy
- Osteoporosis prevention in postmenopausal women
- Estrogen deficiency states
Common side effects
- Breast tenderness
- Vaginal bleeding or spotting
- Headache
- Nausea
- Fluid retention
- Increased risk of venous thromboembolism
- Increased risk of breast cancer (with long-term use)
- Increased risk of endometrial cancer (unopposed estrogen)
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (PHASE1)
- Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer (PHASE1)
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- estrogen therapy CI brief — competitive landscape report
- estrogen therapy updates RSS · CI watch RSS
- Beni-Suef University portfolio CI